Cristina Scielzo

List of Publications by Year
in descending order

54	3,329	186209 28	243529 44
papers	citations	h-index	g-index

55	55	55	4451
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. Haematologica, 2021, 106, 2334-2344.	1.7	18
2	3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology, 2021, 12, 639572.	2.2	26
3	3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 655773.	1.8	3
4	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. OncoImmunology, 2020, 9, 1794359.	2.1	25
5	Modeling the Leukemia Microenviroment In Vitro. Frontiers in Oncology, 2020, 10, 607608.	1.3	23
6	Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control. Scientific Reports, 2019, 9, 4155.	1.6	4
7	A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Nature Communications, 2018, 9, 1787.	5.8	22
8	T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency. Blood, 2018, 132, 2362-2374.	0.6	99
9	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood, 2017, 129, 3440-3451.	0.6	56
10	Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget, 2017, 8, 11219-11227.	0.8	21
11	HIF-1Î± regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood, 2016, 127, 1987-1997.	0.6	52
12	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. Journal of Immunology, 2016, 197, 2522-2531.	0.4	31
13	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell Reports, 2016, 14, 1748-1760.	2.9	90
14	Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. PLoS ONE, 2015, 10, e0130195.	1.1	8
15	Synthetic High-Density Lipoprotein-like Nanoparticles (HDL NP) Cause Apoptosis and Enhance Killing By B-Cell Receptor and BCL-2 Inhibitors in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2949-2949.	0.6	0
16	IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment. Blood, 2015, 126, 2915-2915.	0.6	0
17	How the microenvironment wires the natural history of chronic lymphocytic leukemia. Seminars in Cancer Biology, 2014, 24, 43-48.	4.3	76
18	From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia. Journal of Visualized Experiments, 2014, , e51942.	0.2	2

#	Article	IF	Citations
19	Nurse-like Cells Engage Sigm and Sigd on Chronic Lymphocytic Leukemia (CLL) Cells: Implications for BCR Signaling Activation and Functional Outcome. Blood, 2014, 124, 3312-3312.	0.6	0
20	Anergy in CLL: Moving Towards the Clinic. Blood, 2014, 124, 4677-4677.	0.6	0
21	Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood, 2013, 121, 2264-2273.	0.6	50
22	Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia, 2013, 27, 534-540.	3.3	38
23	Targeting B-cell anergy in chronic lymphocytic leukemia. Blood, 2013, 121, 3879-3888.	0.6	73
24	Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4143-4143.	0.6	0
25	Targeting the LYN/HS1 Signaling Axis in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 928-928.	0.6	0
26	Targeting B Cell Anergy in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3863-3863.	0.6	0
27	The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia, 2011, 25, 1760-1767.	3.3	37
28	General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood, 2011, 118, 6618-6625.	0.6	131
29	A novel Rag2â^'/â^'Î³câ^'/â^'-xenograft model of human CLL. Blood, 2010, 115, 1605-1609.	0.6	58
30	MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood, 2010, 115, 3949-3959.	0.6	101
31	HS1 has a central role in the trafficking and homing of leukemic B cells. Blood, 2010, 116, 3537-3546.	0.6	89
32	CLL-like monoclonal B-cell lymphocytosis: Are we all bound to have it?. Seminars in Cancer Biology, 2010, 20, 384-390.	4.3	47
33	An overview of chronic lymphocytic leukaemia biology. Best Practice and Research in Clinical Haematology, 2010, 23, 21-32.	0.7	22
34	How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leukemia and Lymphoma, 2010, 51, 1371-1374.	0.6	15
35	CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL. Blood, 2010, 116, 2440-2440.	0.6	1
36	Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2009, 144, 507-516.	1.2	116

#	Article	IF	Citations
37	The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)â€“like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood, 2009, 114, 26-32.	0.6	122
38	Novel Mouse Models of Chronic Lymphocytic Leukemia (CLL) Unravel the Molecular Mechanisms Controlling Bone Marrow Involvement by Leukemic B Cells.. Blood, 2009, 114, 360-360.	0.6	3
39	Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood, 2008, 111, 1524-1533.	0.6	285
40	Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood, 2008, 112, 188-195.	0.6	212
41	The Immunoglobulin Gene Repertoire of Low-Count CLL-Like MBL Is Different from CLL: Diagnostic Considerations and Implications for Clinical Monitoring. Blood, 2008, 112, 779-779.	0.6	0
42	Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood, 2007, 109, 5276-5285.	0.6	451
43	HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells. Leukemia, 2007, 21, 2067-2070.	3.3	22
44	Ageâ€dependent accumulation of monoclonal CD4⁺CD8⁺double positive T lymphocytes in the peripheral blood of the elderly. British Journal of Haematology, 2007, 139, 780-790.	1.2	84
45	From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmunity Reviews, 2007, 7, 127-131.	2.5	46
46	A Molecular Signature of Anergy Detected in a Subset of CLL Patients.. Blood, 2007, 110, 742-742.	0.6	1
47	ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia, 2006, 20, 689-695.	3.3	66
48	HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. Journal of Clinical Investigation, 2005, 115, 1644-1650.	3.9	72
49	CD38 modifications in chronic lymphocytic leukemia: are they relevant?. Leukemia, 2004, 18, 1733-1735.	3.3	21
50	Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood, 2004, 103, 2337-2342.	0.6	210
51	The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Experimental Hematology, 2003, 31, 495-503.	0.2	31
52	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood, 2003, 101, 1962-1969.	0.6	139
53	The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood, 2003, 101, 1262-1269.	0.6	221
54	Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. Oncotarget, 0, 7, 41725-41736.	0.8	9